Across all studies, the safety profile was consistent with the broader GLP-1 class: nausea, diarrhea, and mild gastrointestinal symptoms were the most common side effects, typically occurring during the dose escalation phase
Quality concerns have followed too by July 2026, multiple Indian semaglutide manufacturers had recalled batches or delayed supply over quality issues, even as generics came to dominate the market (India Today, July 2026)
Some are legitimate FDA-approved drugssuch as insulin analogs and GLP-1 medications (Ozempic, Mounjaro, Zepbound)backed by decades of safety and efficacy research
[13] For most patients, mild nausea is the only side effect theyll experience, and for many of them the effects will dissipate as their bodies adjust to GLP-1 use
This makes the combination appealing not just for weight loss but for anyone looking to improve their long-term health
& Desnick, R